Associations - MLH1 (MutL homolog 1)

MLH1 mutation	Gastric Cancer	MLH1 mutation	Gastric Cancer	tremelimumab-actl Sensitive: C2 – Inclusion Criteria tremelimumab-actl Sensitive : C2	tremelimumab-actl Sensitive: C2 – Inclusion Criteria tremelimumab-actl Sensitive : C2
MLH1 mutation	Gastric Cancer	MLH1 mutation	Gastric Cancer	durvalumab + tremelimumab-actl Sensitive: C2 – Inclusion Criteria durvalumab + tremelimumab-actl Sensitive : C2	durvalumab + tremelimumab-actl Sensitive: C2 – Inclusion Criteria durvalumab + tremelimumab-actl Sensitive : C2
MLH1 V384D	Non Small Cell Lung Cancer	MLH1 V384D	Non Small Cell Lung Cancer	erlotinib Sensitive: C3 – Early Trials erlotinib Sensitive : C3	erlotinib Sensitive: C3 – Early Trials erlotinib Sensitive : C3
MLH1 V384D	Non Small Cell Lung Cancer	MLH1 V384D	Non Small Cell Lung Cancer	gefitinib Sensitive: C3 – Early Trials gefitinib Sensitive : C3	gefitinib Sensitive: C3 – Early Trials gefitinib Sensitive : C3
MLH1 V384D	Non Small Cell Lung Cancer	MLH1 V384D	Non Small Cell Lung Cancer	icotinib Sensitive: C3 – Early Trials icotinib Sensitive : C3	icotinib Sensitive: C3 – Early Trials icotinib Sensitive : C3
MLH1 deletion	Endometrial Adenocarcinoma	MLH1 deletion	Endometrial Adenocarcinoma	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
MLH1 deletion	Prostate Cancer	MLH1 deletion	Prostate Cancer	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
MSI-H/dMMR + MLH1 deletion + PMS2 deletion	Colorectal Cancer	MSI-H/dMMR + MLH1 deletion + PMS2 deletion	Colorectal Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
MSI-H/dMMR + MLH1 deletion	Colorectal Cancer	MSI-H/dMMR + MLH1 deletion	Colorectal Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
MSI-H/dMMR + MLH1 deletion	Endometrial Cancer	MSI-H/dMMR + MLH1 deletion	Endometrial Cancer	dostarlimab-gxly Sensitive: C3 – Early Trials dostarlimab-gxly Sensitive : C3	dostarlimab-gxly Sensitive: C3 – Early Trials dostarlimab-gxly Sensitive : C3
MLH1 deletion+ PMS2 deletion	Endometrial Cancer	MLH1 deletion+ PMS2 deletion	Endometrial Cancer	dostarlimab-gxly Sensitive: C3 – Early Trials dostarlimab-gxly Sensitive : C3	dostarlimab-gxly Sensitive: C3 – Early Trials dostarlimab-gxly Sensitive : C3
MLH1 mutation	Prostate Cancer	MLH1 mutation	Prostate Cancer	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3
MLH1 mutation	HER2 Positive Breast Cancer	MLH1 mutation	HER2 Positive Breast Cancer	trastuzumab Resistant: C3 – Early Trials trastuzumab Resistant : C3	trastuzumab Resistant: C3 – Early Trials trastuzumab Resistant : C3
PMS2 mutation + MLH1 mutation	Gastric Cancer	PMS2 mutation + MLH1 mutation	Gastric Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
PMS2 mutation + MLH1 mutation	Colorectal Cancer	PMS2 mutation + MLH1 mutation	Colorectal Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
MLH1 deletion+ PMS2 deletion	Rectal Cancer	MLH1 deletion+ PMS2 deletion	Rectal Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
MLH1 methylation + MSI-H/dMMR + TMB-H	Endometrial Cancer	MLH1 methylation + MSI-H/dMMR + TMB-H	Endometrial Cancer	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3
MLH1 methylation + MSI-H/dMMR	Endometrial Cancer	MLH1 methylation + MSI-H/dMMR	Endometrial Cancer	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3
MLH1 mutation	Urothelial Cancer	MLH1 mutation	Urothelial Cancer	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4
MSH6 mutation + MLH1 mutation + MSI-H	Squamous Cell Skin Cancer	MSH6 mutation + MLH1 mutation + MSI-H	Squamous Cell Skin Cancer	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4
MSI-H/dMMR + MLH1 deletion + PMS2 deletion	Esophageal Adenocarcinoma	MSI-H/dMMR + MLH1 deletion + PMS2 deletion	Esophageal Adenocarcinoma	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4
PMS2 mutation + MLH1 mutation	Prostate Cancer	PMS2 mutation + MLH1 mutation	Prostate Cancer	nivolumab + ipilimumab Sensitive: C4 – Case Studies nivolumab + ipilimumab Sensitive : C4	nivolumab + ipilimumab Sensitive: C4 – Case Studies nivolumab + ipilimumab Sensitive : C4
MSI-H/dMMR + MLH1 deletion + PMS2 deletion	Colorectal Cancer	MSI-H/dMMR + MLH1 deletion + PMS2 deletion	Colorectal Cancer	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4
MSI-H/dMMR + MLH1 negative + PMS2 negative	Gastroesophageal Junction Adenocarcinoma	MSI-H/dMMR + MLH1 negative + PMS2 negative	Gastroesophageal Junction Adenocarcinoma	nivolumab + ipilimumab Sensitive: C4 – Case Studies nivolumab + ipilimumab Sensitive : C4	nivolumab + ipilimumab Sensitive: C4 – Case Studies nivolumab + ipilimumab Sensitive : C4
MLH1 mutation	Urothelial Cancer	MLH1 mutation	Urothelial Cancer	nivolumab + ipilimumab Sensitive: C4 – Case Studies nivolumab + ipilimumab Sensitive : C4	nivolumab + ipilimumab Sensitive: C4 – Case Studies nivolumab + ipilimumab Sensitive : C4
ER positive + MLH1 1835del3 + MSI-H/dMMR + TMB-H	HER2 Negative Breast Cancer	ER positive + MLH1 1835del3 + MSI-H/dMMR + TMB-H	HER2 Negative Breast Cancer	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4
MLH1 deletion	Colon Cancer	MLH1 deletion	Colon Cancer	cetuximab Resistant: D – Preclinical cetuximab Resistant : D	cetuximab Resistant: D – Preclinical cetuximab Resistant : D

MLH1 (MutL homolog 1)

Associations(27)

Associations
(27)